Welcome to our dedicated page for Nuvalent SEC filings (Ticker: NUVL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Nuvalent, Inc. (NUVL) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Nuvalent is a clinical-stage biopharmaceutical company listed on The Nasdaq Global Select Market, and its filings offer detailed information on clinical progress, financing activities, and key business agreements related to its targeted oncology pipeline.
Recent Form 8-K filings describe pivotal and preliminary data for neladalkib in ALK-positive NSCLC from the ALKOVE-1 Phase 1/2 trial, pivotal data for zidesamtinib in ROS1-positive NSCLC from the ARROS-1 Phase 1/2 trial, and the initiation of the ALKAZAR Phase 3 trial in TKI-naïve ALK-positive NSCLC. Other 8-Ks outline the completion and FDA acceptance of a New Drug Application for zidesamtinib in TKI pre-treated ROS1-positive NSCLC, plans for an NDA submission for neladalkib, and the assignment of a PDUFA target action date for zidesamtinib.
Filings also document Nuvalent’s capital markets activity, including an underwriting agreement for a public offering of Class A common stock under an automatically effective shelf registration statement on Form S-3, and the company’s estimate that proceeds from the offering, together with existing cash, cash equivalents, and marketable securities, would fund operations into 2029. Additional disclosures cover a preexisting royalty interest on future net sales of neladalkib and zidesamtinib, as well as periodic 8-Ks furnishing quarterly financial results press releases.
On Stock Titan, these SEC filings are paired with AI-powered summaries that highlight the main points of each document, helping readers quickly understand clinical data updates, NDA milestones, financing terms, and other material events. Users can review 10-K and 10-Q reports, 8-K current reports, registration statements, and exhibits, and use the AI-generated insights to navigate lengthy technical and legal language more efficiently while researching NUVL.
Nuvalent, Inc. filed a current report to share that it announced its financial results for the quarter ended September 30, 2025, along with other corporate updates. The company furnished a press release as Exhibit 99.1, which contains the detailed quarterly results and information. This material is being treated as “furnished” rather than “filed,” meaning it is not subject to certain liability provisions under the securities laws or automatically incorporated into other SEC filings unless specifically referenced.
Nuvalent (NUVL) director Matthew D. Shair reported open-market sales of Class A common stock executed under a Rule 10b5-1 trading plan adopted on November 20, 2024.
On 10/27/2025, he sold 14,345 shares at a weighted average price of $100.23 and 4,046 shares held indirectly by the Matthew D. Shair 2021 Irrevocable Family Trust at a weighted average price of $100.23. On 10/28/2025, he sold 32,455 shares at a weighted average price of $100.27 and 9,154 indirect shares at a weighted average price of $100.27. Following these transactions, he beneficially owned 1,383,044 shares directly and 203,322 shares indirectly.
Nuvalent, Inc. (NUVL) reported an insider transaction by its Chief Legal Officer. On 10/20/2025, the officer exercised 5,000 stock options at an exercise price of $6.89 per share and sold 5,000 Class A shares at a weighted average price of $94.91 (range $94.80–$95.00). These trades were executed under a Rule 10b5-1 trading plan adopted on November 18, 2024.
Following the transactions, the reporting person directly beneficially owned 49,086 Class A shares and held 140,608 derivative securities (stock options) with an option expiration date of 04/29/2031. The filing notes the underlying option shares are fully vested.
Nuvalent (NUVL): CEO insider transaction — On 10/16/2025, the President and CEO (also a Director) exercised 27,000 stock options at $18.93 per share and sold an aggregate 27,000 Class A shares in multiple tranches pursuant to a Rule 10b5-1 trading plan.
Weighted-average sale prices by tranche were $90.01 for 11,310 shares, $90.91 for 13,876 shares, $92.19 for 1,114 shares, and $92.63 for 700 shares. Following these transactions, the reporting person beneficially owned 249,062 Class A shares directly. Derivative holdings reported include 222,400 stock options remaining after the exercise.
Nuvalent, Inc. (NUVL): The Chief Legal Officer reported option exercises and open-market sales under a Rule 10b5-1 plan. On 10/15/2025, 15,624 Class A shares were acquired via option exercise at $6.89 and 15,624 shares were sold at a weighted average price of $89.98. On 10/16/2025, 12,376 shares were acquired via option exercise at $6.89, followed by sales of 2,277 shares at a weighted average price of $90.54, 5,199 shares at $91.37, and 4,900 shares at $92.5.
Following these transactions, the reporting person directly owned 49,086 Class A shares. The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on November 18, 2024. After the exercises, stock options (right to buy) remaining were 145,608 at a $6.89 exercise price, fully vested, expiring on 04/29/2031.
Nuvalent (NUVL) reported insider activity by its Chief Scientific Officer. On 10/15/2025, the officer exercised stock options for 3,668 shares at $18.93, 7,495 shares at $27.85, and 3,042 shares at $72.35, then sold 14,205 Class A shares at a weighted average price of $90.04 (range $89.84–$90.23).
The transactions were made under a Rule 10b5-1 trading plan adopted on November 1, 2024. Following these trades, the officer directly beneficially owned 65,963 Class A shares.
Nuvalent (NUVL) reported an insider transaction by its Chief Financial Officer. On 10/15/2025, the CFO exercised 1,683 stock options at $18.93 per share and sold 1,683 Class A shares at a weighted average price of $85.57, with individual sales ranging from $85.00 to $85.69. The trades were made under a Rule 10b5-1 plan adopted on December 12, 2024.
Following these transactions, the CFO beneficially owned 61,734 Class A shares directly and 28,979 derivative securities (stock options). The filing lists transaction codes M (option exercise) and S (sale).
Nuvalent (NUVL) insider activity: The Chief Scientific Officer reported option exercises and open‑market sales on 10/13/2025 and 10/14/2025 under a Rule 10b5-1 trading plan adopted on November 1, 2024.
Exercises included Class A Common Stock options for 1,669 at $18.93, 4,168 at $27.85, and 1,800 at $72.35 on 10/13, and 731 at $18.93, 877 at $27.85, and 825 at $29.33 on 10/14. Sales included 7,637 at a weighted average price of $89.81 on 10/13 (range $89.80–$89.83), and on 10/14: 1,167 at $84.98 (range $84.64–$85.63), 866 at $86.11 (range $85.89–$86.81), and 400 at $87.39 (range $87.33–$87.56).
Following the reported transactions, the reporting person beneficially owned 65,963 Class A Common Stock shares directly.
Nuvalent (NUVL) reported insider transactions by its Chief Financial Officer. On 10/13/2025 and 10/14/2025, the CFO exercised employee stock options and sold shares pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024.
On 10/13, options for 6,875 shares at $6.89 and 13,125 shares at $18.93 were exercised, followed by sales totaling 20,000 shares at weighted-average prices within disclosed ranges of $87.15–$89.28. On 10/14, 20,000 options at $18.93 were exercised and 20,000 shares were sold at weighted-average prices within $85.17–$89.12. Following these transactions, the CFO beneficially owned 61,734 Class A shares directly and 30,662 options remained outstanding.
Alexandra Balcom, Chief Financial Officer of Nuvalent, Inc. (NUVL), reported multiple transactions on 10/01/2025 under a Rule 10b5-1 trading plan adopted on 12/12/2024. The filing shows purchases (option exercises) totaling 20,000 shares acquired at exercise prices of $6.89 and $18.93, and open stock option holdings of 20,000 underlying shares exercisable through 2031 and 2032. Balcom sold 20,000 Class A shares in two weighted-average-price blocks: 19,030 shares at an average of $85.43 and 970 shares at an average of $86.37, leaving 61,734 Class A shares beneficially owned after the transactions. The filing was signed by an attorney-in-fact on 10/03/2025.
FAQ
What is the current stock price of Nuvalent (NUVL)?
What is the market cap of Nuvalent (NUVL)?
